$HROW SEC Filings

Filed On	Filing
27 Oct 2026	SCHEDULE 13G/A
05 Oct 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise
04 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation
21 Aug 2026	144
17 Aug 2026	Form 4: Shojaei Amir, CHIEF SCIENTIFIC OFFICER Received 11,250 shares by exercise or conversion ($405K) · Sold 11,250 shares ($450K)
10 Aug 2026	10-Q
10 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
06 Aug 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
31 Jul 2026	SCHEDULE 13G/A
22 Jun 2026	Form 4: Sternberg Perry J., Director Granted 5,248 RSU
22 Jun 2026	Form 4: Silvernail Lauren P, Director Granted 5,248 RSU
22 Jun 2026	Form 4: Graves Adrienne L, Director Granted 5,248 RSU
22 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
03 Jun 2026	8-K: Regulation FD Disclosure
19 May 2026	Form 4: Graves Adrienne L, Director Bought 1,000 shares ($31.1K)
19 May 2026	Form 4: Silvernail Lauren P, Director Bought 1,000 shares ($31K)
18 May 2026	Form 4: Shojaei Amir, CHIEF SCIENTIFIC OFFICER Granted 10,000 Restricted Stock Units
15 May 2026	Form 4: Baum Mark L, Director Bought 10,000 shares ($302K)
15 May 2026	Form 4: Boll Andrew R., PRESIDENT AND CFO Bought 3,500 shares ($105K)
11 May 2026	10-Q

Comments